PATENT CLAIM ANALYSIS

Application Number: 15744485
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "492000"]

Abstract:
Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.

Claim (Index 35):
The method of any of  claims 1 - 34 , wherein the selective OCT2 inhibitor is administered at a dose that results in its plasma concentration during the period of platinum drug administration less than its maximum tolerated plasma concentration (MTC) and greater than 1\u00d7, 2\u00d7, 3\u00d7, 4\u00d7 of its IC 50  value for OCT2-mediated transport of 20 \u03bcM oxaliplatin assessed in human serum or an assay buffer containing 4% bovine serum albumin.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 86.0
- Lexical Diversity: 1.83333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12836398', '13147751', '14175295', '11638193', '15314200']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7860766946238588
- 35 USC 102 Novelty (BERT): 0.5138778456053048
- Combined Prediction Score: 0.7588568097220034
- Mean Citation Score: 256.733086
- Max Citation Score: 260.66200000000003
- Similarity Product: 161.42964106166366

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test